IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 217 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.62 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,087,466 | -35.4% | 678,564 | 0.0% | 0.18% | -33.2% |
| Q2 2023 | $4,777,091 | +15.2% | 678,564 | 0.0% | 0.26% | +28.4% |
| Q1 2023 | $4,146,026 | -4.4% | 678,564 | 0.0% | 0.20% | -10.9% |
| Q4 2022 | $4,336,024 | -33.3% | 678,564 | 0.0% | 0.23% | -49.6% |
| Q3 2022 | $6,501,000 | -13.2% | 678,564 | 0.0% | 0.45% | -3.8% |
| Q2 2022 | $7,491,000 | -33.7% | 678,564 | 0.0% | 0.47% | -3.7% |
| Q1 2022 | $11,298,000 | -12.8% | 678,564 | 0.0% | 0.49% | +10.4% |
| Q4 2021 | $12,954,000 | -22.6% | 678,564 | 0.0% | 0.44% | -64.2% |
| Q3 2021 | $16,733,000 | -5.2% | 678,564 | 0.0% | 1.24% | +6.4% |
| Q2 2021 | $17,656,000 | -5.4% | 678,564 | +15.1% | 1.17% | -10.6% |
| Q1 2021 | $18,664,000 | -22.8% | 589,516 | +13.1% | 1.30% | -2.6% |
| Q4 2020 | $24,180,000 | +28.2% | 521,120 | -9.0% | 1.34% | -41.9% |
| Q3 2020 | $18,862,000 | +6.6% | 572,971 | -11.1% | 2.30% | -23.5% |
| Q2 2020 | $17,698,000 | -8.3% | 644,728 | 0.0% | 3.01% | -33.2% |
| Q1 2020 | $19,300,000 | -31.7% | 644,728 | -36.9% | 4.50% | -18.1% |
| Q4 2019 | $28,271,000 | +52.1% | 1,021,361 | 0.0% | 5.50% | +44.0% |
| Q3 2019 | $18,589,000 | -22.3% | 1,021,361 | 0.0% | 3.82% | -24.5% |
| Q2 2019 | $23,919,000 | +158.8% | 1,021,361 | 0.0% | 5.06% | +117.6% |
| Q1 2019 | $9,241,000 | +6.3% | 1,021,361 | 0.0% | 2.32% | -18.0% |
| Q4 2018 | $8,696,000 | -0.6% | 1,021,361 | +24.3% | 2.84% | +25.5% |
| Q3 2018 | $8,748,000 | -16.8% | 821,361 | 0.0% | 2.26% | -25.2% |
| Q2 2018 | $10,513,000 | -53.3% | 821,361 | -41.8% | 3.02% | +27.8% |
| Q1 2018 | $22,534,000 | +161.6% | 1,411,695 | +25.6% | 2.36% | +386.2% |
| Q4 2017 | $8,615,000 | +71.6% | 1,124,295 | +70.1% | 0.49% | +159.9% |
| Q3 2017 | $5,019,000 | +7.0% | 660,809 | 0.0% | 0.19% | +49.6% |
| Q2 2017 | $4,690,000 | – | 660,809 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Perceptive Advisors | 12,201,261 | $203,150,000 | 4.07% |
| Paradigm Biocapital Advisors LP | 907,428 | $15,109,000 | 4.00% |
| Avoro Capital Advisors LLC | 9,125,000 | $151,931,000 | 2.77% |
| Logos Global Management LP | 1,000,000 | $16,650,000 | 2.16% |
| Avidity Partners Management LP | 6,043,219 | $100,620,000 | 2.10% |
| Orbimed Advisors | 6,633,006 | $110,440,000 | 1.79% |
| Parametrica Management Ltd | 134,679 | $2,240,000 | 1.66% |
| Boxer Capital, LLC | 1,935,133 | $32,220,000 | 1.66% |
| Fairmount Funds Management LLC | 389,588 | $6,487,000 | 1.53% |
| Long Focus Capital Management, LLC | 705,000 | $11,738,000 | 1.51% |